<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d166">
    <sentence id="DDI-MedLine.d166.s0" text="Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.&#xd;&#xa;">
        <entity id="DDI-MedLine.d166.s0.e0" charOffset="40-49"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s0.e1" charOffset="83-93"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s0.p0" e1="DDI-MedLine.d166.s0.e0"
            e2="DDI-MedLine.d166.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s1" text="Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. ">
        <entity id="DDI-MedLine.d166.s1.e0" charOffset="75-88"
            type="drug" text="erythropoietin"/>
        <entity id="DDI-MedLine.d166.s1.e1" charOffset="91-93"
            type="drug" text="EPO"/>
        <pair id="DDI-MedLine.d166.s1.p0" e1="DDI-MedLine.d166.s1.e0"
            e2="DDI-MedLine.d166.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s2" text="Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ">
        <entity id="DDI-MedLine.d166.s2.e0" charOffset="23-32"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s2.e1" charOffset="118-128"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s2.p0" e1="DDI-MedLine.d166.s2.e0"
            e2="DDI-MedLine.d166.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s3" text="METHODS AND AIMS: We conducted a retrospective cohort study of 40 end-stage renal disease (ESRD) patients (age: 55    14; mean    SD; 21:male) who had at least 12 months of cinacalcet therapy. ">
        <entity id="DDI-MedLine.d166.s3.e0" charOffset="173-182"
            type="drug" text="cinacalcet"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s4" text="The distribution of renal replacement therapies were: 14 peritoneal dialysis, 18 conventional hemodialysis and 8 nocturnal hemodialysis. "/>
    <sentence id="DDI-MedLine.d166.s5" text="Standard dialysis related biochemical indices and medications used were recorded. "/>
    <sentence id="DDI-MedLine.d166.s6" text="The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ">
        <entity id="DDI-MedLine.d166.s6.e0" charOffset="70-80"
            type="drug" text="darbepoetin"/>
        <entity id="DDI-MedLine.d166.s6.e1" charOffset="127-136"
            type="drug" text="cinacalcet"/>
        <pair id="DDI-MedLine.d166.s6.p0" e1="DDI-MedLine.d166.s6.e0"
            e2="DDI-MedLine.d166.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s7" text="Our secondary objective was to determine if there was a relationship between the changes in PTH and darbepoetin requirement.">
        <entity id="DDI-MedLine.d166.s7.e0" charOffset="100-110"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s8" text="Overall, PTH levels decreased from 197.5 (151.8; 249.2) to 66.1 (41.2; 136.5) (median (25th;75th percentile)) pmol/l; "/>
    <sentence id="DDI-MedLine.d166.s9" text="p &amp;lt; "/>
    <sentence id="DDI-MedLine.d166.s10" text="0.001. "/>
    <sentence id="DDI-MedLine.d166.s11" text="Cinacalcet dose increased from 30.0   6 to 63   25 mg/day, p &lt;">
        <entity id="DDI-MedLine.d166.s11.e0" charOffset="0-9"
            type="drug" text="Cinacalcet"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s12" text="0.05. "/>
    <sentence id="DDI-MedLine.d166.s13" text="Hemoglobin remained unchanged (116   13 to 116   13 g/l), while darbepoetin requirement decreased from 40 (20; 60) to 24 (19; 59)   g/week, p = 0.02.">
        <entity id="DDI-MedLine.d166.s13.e0" charOffset="64-74"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s14" text="The remainder of the dialysis-related biochemistry (electrolytes, calcium, phosphate, iron status) and vitamin D use remained unchanged. "/>
    <sentence id="DDI-MedLine.d166.s15" text="A reduction in PTH level of greater than 30% was experienced by 82.5% (33/40) of our cohort. "/>
    <sentence id="DDI-MedLine.d166.s16" text="Among the responders, the fall in PTH and reduction darbepoetin requirement were related (R = -0.48, p = 0.004). ">
        <entity id="DDI-MedLine.d166.s16.e0" charOffset="52-62"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s17" text="Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ">
        <entity id="DDI-MedLine.d166.s17.e0" charOffset="20-29"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s17.e1" charOffset="64-74"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s17.p0" e1="DDI-MedLine.d166.s17.e0"
            e2="DDI-MedLine.d166.s17.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s18" text="The interface between bone and bone marrow in uremia represents a critical step in red blood cell production which merits further investigation."/>
</document>
